Cardiff Oncology (FRA:XE7C) Cyclically Adjusted Book per Share: €6.07 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:XE7C Cardiff Oncology Inc FRA:XE7C
31 GF Score
Price €0.77
! 5 Warning Signs
View Full Analysis

What is Cardiff Oncology Cyclically Adjusted Book per Share?

Cardiff Oncology FRA:XE7C -0.83% 31 Cyclically Adjusted Book per Share is €6.07 as of Jun. 2026. GuruFocus rates FRA:XE7C with a GF Score™ of 31/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Cardiff Oncology's adjusted book value per share for the three months ended in Jun. 2026 was €0.336. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €6.07 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Cardiff Oncology's average Cyclically Adjusted Book Growth Rate was -65.00% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -27.50% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -14.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Cardiff Oncology was -1.50% per year. The lowest was -27.50% per year. And the median was -9.10% per year.

As of today (2026-08-16), Cardiff Oncology's current stock price is €0.773. Cardiff Oncology's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 was €6.07. Cardiff Oncology's Cyclically Adjusted PB Ratio of today is 0.13.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Cardiff Oncology was 0.70. The lowest was 0.03. And the median was 0.12.


Cardiff Oncology  (FRA:XE7C) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cardiff Oncology's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.773/6.07
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Cardiff Oncology was 0.70. The lowest was 0.03. And the median was 0.12.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Cardiff Oncology Cyclically Adjusted Book per Share Related Terms


Cardiff Oncology Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Cardiff Oncology's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiff Oncology Cyclically Adjusted Book per Share Chart

Cardiff Oncology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.92 31.27 26.96 23.65 11.53

Cardiff Oncology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.27 14.23 11.53 8.23 6.07

FRA:XE7C vs MNOV, PMVP, CING: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Cardiff Oncology's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiff Oncology Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Cyclically Adjusted PB Ratio falls into.


FRA:XE7C
31GF Score
Cardiff Oncology Inc FRA:XE7C
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cardiff Oncology Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cardiff Oncology's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book= Book Value per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.336/333.9520*333.9520
=0.336

Current CPI (Jun. 2026) = 333.9520.

Cardiff Oncology Quarterly Data

Book Value per Share CPI Adj_Book
201609 56.132 241.428 77.644
201612 43.991 241.432 60.849
201703 23.223 243.801 31.810
201706 7.234 244.955 9.862
201709 6.257 246.819 8.466
201712 7.501 246.524 10.161
201803 4.645 249.554 6.216
201806 5.187 251.989 6.874
201809 3.131 252.439 4.142
201812 2.313 251.233 3.075
201903 1.894 254.202 2.488
201906 1.439 256.143 1.876
201909 0.939 256.759 1.221
201912 0.766 256.974 0.995
202003 0.505 258.115 0.653
202006 1.015 257.797 1.315
202009 1.083 260.280 1.390
202012 2.864 260.474 3.672
202103 2.792 264.877 3.520
202106 2.915 271.696 3.583
202109 2.870 274.310 3.494
202112 2.961 278.802 3.547
202203 2.728 287.504 3.169
202206 2.632 296.311 2.966
202209 2.639 296.808 2.969
202212 2.247 296.797 2.528
202303 2.017 301.836 2.232
202306 1.789 305.109 1.958
202309 1.632 307.789 1.771
202312 1.431 306.746 1.558
202403 1.253 312.332 1.340
202406 1.067 314.175 1.134
202409 0.913 315.301 0.967
202412 1.191 315.605 1.260
202503 0.985 319.799 1.029
202506 0.764 322.561 0.791
202509 0.620 324.800 0.637
202512 0.567 324.054 0.584
202603 0.439 330.213 0.444
202606 0.336 333.952 0.336

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €6.07 mean?
Cardiff Oncology (FRA:XE7C) has a Cyclically Adjusted Book per Share of €6.07 as of Jun. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Cardiff Oncology and its competitors.
Is Cardiff Oncology's Cyclically Adjusted Book per Share too high?
Cardiff Oncology's current Cyclically Adjusted Book per Share is €6.07. Overall, Cardiff Oncology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Cyclically Adjusted Book per Share compare to MNOV and PMVP?
Cardiff Oncology's Cyclically Adjusted Book per Share of €6.07 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Cardiff Oncology and its competitors. Cardiff Oncology's current Cyclically Adjusted Book per Share is €6.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Cardiff Oncology (FRA:XE7C) has a current Cyclically Adjusted Book per Share of €6.07. The current Cyclically Adjusted Book per Share is €6.07. Cardiff Oncology's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Cardiff Oncology (FRA:XE7C), the current Cyclically Adjusted Book per Share is €6.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiff Oncology Business Description

Other Exchanges CRDF:USAXE7C:Germany
Address 11055 Flintkote Avenue, San Diego, CA, USA, 92121
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
31GF Score

Get the complete analysis for FRA:XE7C

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.77
Price